Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
A phase II study of PTK787 in...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
A phase II study of PTK787 in metastatic melanoma patients
Bibliographic Details
Main Authors:
Corrie, P
,
Kareclas, P
,
Mann, C
,
Palmer, C
,
Thomas, A
,
Nicholson, S
,
Morgan, B
,
Lomas, D
,
Middleton, M
Format:
Journal article
Published:
2008
Holdings
Description
Similar Items
Staff View
Similar Items
A phase 2 study of vatalanib in metastatic melanoma patients.
by: Cook, N, et al.
Published: (2010)
A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients
by: Pavel, M, et al.
Published: (2005)
Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis
by: Marlies H.G. Langenberg, et al.
Published: (2010-02-01)
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
by: Giatromanolaki, A, et al.
Published: (2012)
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
by: Hecht, JR, et al.
Published: (2011)